Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD
Wednesday, September 30, 2026 · 9 min
Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.
Listen
Show notes
Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.
In this episode
- Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page
Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page # Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme Swapnadip Roy and Vicky Ramancha were indicted on smuggling and conspiracy charges for distributing counterfeit Ozempic, with Roy appearing in a Florida federal court following his extradition from Italy. via CBS…
- Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes # Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes By PR Newswire | September 29, 2026, 6:00 PM In…
- Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma
Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan # Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan By Fraiser Kansteiner Sep 29, 2026 11:20am Finding unique features to pin one’s GLP-1 pitch on has become increasingly important both for developers hoping to catch the next wave of obesity treatments and for Novo’s and Lilly’s…
- Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! News Release 28-Sep-2026 # Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway New research to be presented at the Annual Meeting of…
- Step Back — With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?
Background sources
- FDA warns consumers not to use counterfeit Ozempic ... — Fda
- Office of Public Affairs | Two Indian Nationals Charged in Connection with Transnational Counterfeit Ozempic Scheme | United States Department of Justice — United States Department of Justice
- FDA's Concerns with Unapproved GLP-1 Drugs Used for ... — Fda
- Compounded GLP-1s: Why doctors worry and the FDA is ... — Stanford